| Literature DB >> 31155444 |
Cléa Melenotte1, Julie Seguier1, Mikael Ebbo1, Elsa Kaphan2, Emmanuelle Bernit1, Laurent Saillier3, Bertrand Audoin2, Delphine Feyeux4, Laurent Daniel5, Pierre-Hugues Roche6, Thomas Graillon7, Henry Dufour7, Clémence Boutière2, Nadine Girard8, Fabienne Closs-Prophette9, Constance Guillaud10, Nathalie Tieulié11, Alexis Regent12, Jean Robert Harlé1, Mohamed Hamidou13, Arsène Mekinian14, Aurélie Grados15, Nicolas Schleinitz16.
Abstract
Pachymeningitis is rare, either idiopathic or secondary to inflammatory disorders, after tumoral, surgical or infectious causes have been excluded. The fibroinflammatory IgG4-related disease is one of the etiologies of pachymeningitis with only few cases reported yet. From a single referral regional center, we evaluated the frequency of IgG4-related disease as the cause of inflammatory pachymeningitis in 10% of cases. From a National case registry of IgG4-related disease the pachymeningitis frequency was 4.1%. We report eight new cases with cranial, spinal or both involvements and a literature review of 46 pathological proven cases. We observed that IgG4-related pachymeningitis is in most cases not associated to extra-neurological manifestations of the disease. Only 27% of spinal and 40% of cranial IgG4-related pachymeningitis are associated with other disease localizations. First line treatment strategies included surgery and steroids. The use of immunosuppressants or rituximab was necessary in 18% of spinal and 54% of cranial localizations. Some patients remained with sequellae and clinical and/or radiological improvement can be difficult to obtain.Entities:
Keywords: Hypertrophic meningitis; IgG4-related disease; Pachymenigitis
Year: 2019 PMID: 31155444 DOI: 10.1016/j.semarthrit.2019.05.003
Source DB: PubMed Journal: Semin Arthritis Rheum ISSN: 0049-0172 Impact factor: 5.532